Gins4-flox 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Gins4-flox 基因敲除小鼠

产品编号

S-CKO-00747

品系全称

C57BL/6JCya-Gins4em1flox/Cya

品系背景

C57BL/6JCya

品系编号

CKOCMP-109145-Gins4-B6J-VA

品系状态

使用本品系发表的文献需注明: Gins4-flox 基因敲除小鼠 mice (Strain S-CKO-00747) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量
cKO小鼠库模型

基本信息

基因研究概述

质控标准

基因
基因全称
GINS complex subunit 4
基因别称
2810037C03Rik,4933405K01Rik,Sld5
染色体号
Chr 8 (Mouse)
转录本 ID
NCBI: NM_024240.6 | Ensembl: ENSMUST00000033950
修饰方式
条件性基因敲除
靶向范围
Exon 5~6
敲除长度
~788 bp
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:1923847Homozygous mutant animals do not survive past implantation.
GINS4是GINS复合物的一个亚单位,GINS复合物由GINS1、GINS2、GINS3和GINS4组成,对于真核生物的DNA复制和细胞周期G1/S期的延长至关重要,发挥着重要的生理功能。GINS4在DNA复制过程中起着关键作用,它参与DNA复制的起始和延伸,对于细胞周期的正常进行至关重要。

GINS4在多种癌症中表达上调,与不良预后相关。例如,在肝细胞癌(HCC)中,GINS4的表达上调与肿瘤进展和不良生存相关[2]。GINS4在乳腺癌中也表达上调,并且与不良预后相关[3]。此外,GINS4在食管鳞状细胞癌(ESCC)和胶质瘤中也表达上调,并且与不良预后相关[4][5]。在结直肠癌中,GINS4的表达上调与肿瘤进展和不良预后相关[1]。在胃癌中,GINS4通过激活Rac1和CDC42促进肿瘤生长和进展[7]。在肺癌中,GINS4的表达上调与肿瘤进展和不良预后相关,并且miR-133a-3p可以负向调节GINS4的表达[8]。此外,miR-486-5p和miR-486-3p也可以负向调节GINS4的表达,从而抑制肿瘤的进展[9]。

除了在肿瘤中的表达上调,GINS4的突变也与某些疾病相关。例如,GINS4的杂合缺失突变导致自然杀伤细胞缺陷和粒细胞减少症[6]。这些突变影响GINS复合物的表达和组装,导致细胞周期进程延迟,但不影响DNA合成或增加复制应激。

GINS4在多种癌症中表达上调,与不良预后相关。GINS4的突变也与某些疾病相关。GINS4的研究有助于深入理解其在肿瘤发生发展中的作用和机制,为癌症的治疗和预防提供新的思路和策略。

参考文献:
1. Liu, Zaoqu, Weng, Siyuan, Dang, Qin, Sun, Zhenqiang, Han, Xinwei. 2022. Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer. In eLife, 11, . doi:10.7554/eLife.81114. https://pubmed.ncbi.nlm.nih.gov/36345721/
2. Zhang, Ziying, Chen, Peng, Xie, Hui, Cao, Peiguo. 2021. Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma. In Frontiers in oncology, 11, 654185. doi:10.3389/fonc.2021.654185. https://pubmed.ncbi.nlm.nih.gov/33842367/
3. Li, Hongtao, Cao, Yanzhen, Ma, Jing, Luo, Lin, Ma, Binlin. . Expression and prognosis analysis of GINS subunits in human breast cancer. In Medicine, 100, e24827. doi:10.1097/MD.0000000000024827. https://pubmed.ncbi.nlm.nih.gov/33725952/
4. Jin, Donghui, Yuan, Ligong, Li, Feng, Wang, Shuaibo, Mao, Yousheng. 2022. GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers. In BMC medical genomics, 15, 75. doi:10.1186/s12920-022-01223-x. https://pubmed.ncbi.nlm.nih.gov/35365175/
5. Liu, Binfeng, Liu, Zhendong, Wang, Yanbiao, Zhao, Yaoye, Gao, Yanzheng. 2021. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients. In Molecular medicine (Cambridge, Mass.), 27, 117. doi:10.1186/s10020-021-00378-0. https://pubmed.ncbi.nlm.nih.gov/34556022/
6. Conte, Matilde I, Poli, M Cecilia, Taglialatela, Angelo, Mace, Emily M, Orange, Jordan S. 2022. Partial loss-of-function mutations in GINS4 lead to NK cell deficiency with neutropenia. In JCI insight, 7, . doi:10.1172/jci.insight.154948. https://pubmed.ncbi.nlm.nih.gov/36345943/
7. Zhu, Zhonglin, Yu, Zhilong, Rong, Zeyin, Qiu, Zhengjun, Huang, Chen. 2019. The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42. In Theranostics, 9, 8294-8311. doi:10.7150/thno.36256. https://pubmed.ncbi.nlm.nih.gov/31754397/
8. Zhou, Yafu, Yan, Jianhua, Chen, Huiguo, Zhou, Wenwu, Yang, Jinsong. 2022. MicroRNA-133a-3p Inhibits Lung Adenocarcinoma Development and Cisplatin Resistance through Targeting GINS4. In Cells, tissues, organs, 213, 55-66. doi:10.1159/000527684. https://pubmed.ncbi.nlm.nih.gov/36273455/
9. Tomioka, Yuya, Suetsugu, Takayuki, Seki, Naohiko, Inoue, Hiromasa, Mizuno, Keiko. 2023. The Molecular Pathogenesis of Tumor-Suppressive miR-486-5p and miR-486-3p Target Genes: GINS4 Facilitates Aggressiveness in Lung Adenocarcinoma. In Cells, 12, . doi:10.3390/cells12141885. https://pubmed.ncbi.nlm.nih.gov/37508549/